ZetrOZ Systems

ZetrOZ Systems is a US-based company focused on developing non-invasive medical devices that enhance tissue healing and alleviate chronic pain, primarily through innovative ultrasound therapy solutions. Founded in 2009, ZetrOZ Systems specializes in non-invasive medical technologies aimed at improving patient outcomes. The company has undergone no significant changes in strategy or operations. ZetrOZ is headquartered in the United States, and its recent funding history includes a total of USD 3.

00 mn raised across 9 deals, with the latest round being a Grant of USD 0. 40 mn from the National Institute of Health in October 2020. ZetrOZ Systems specializes in the development and manufacturing of non-invasive medical devices aimed at accelerating tissue healing and alleviating pain associated with chronic musculoskeletal conditions. The company's flagship product, the sustained acoustic medicine (sam®) device, delivers ultrasound therapy that enhances tissue recovery and promotes the body’s natural healing processes.

Designed for both acute and chronic conditions, these devices have been utilized in various clinical settings, including sports medicine, where they support athletes in recovery and pain management. ZetrOZ's customer base includes healthcare providers, sports organizations, and patients, with a focus on markets across North America, Europe, and Asia. The company operates with a commitment to patient-focused solutions backed by over 46 patents, ensuring its products are recognized as leading-edge within the medical technology landscape. ZetrOZ Systems generates revenue through direct sales of its medical devices, particularly the patented sam® product line.

The business model centers around B2B transactions with healthcare providers, sports teams, and rehabilitation centers, facilitating the distribution of their products to end-users. The company offers flexible pricing structures tailored to its client base, allowing for both individual sales and potentially larger contracts with institutional clients. This structure supports a consistent revenue stream as organizations integrate ZetrOZ’s offerings into their treatment protocols, enhancing patient care while driving demand for the advanced healing technologies provided. The company maintains a strong presence in the healthcare market, leveraging its innovative technology to create partnerships and expand its reach.

ZetrOZ Systems plans to enhance its product offerings by developing new devices aimed at improving patient care, with specific details on release dates yet to be announced. The company intends to expand into new geographic markets, specifically targeting Europe and Asia by late 2023. The recent Grant funding of USD 0. 40 mn will support these initiatives, including product development and market entry strategies.